Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep;49(3):192-197.

Heparin: Effects upon the Glycocalyx and Endothelial Cells

Affiliations
Review

Heparin: Effects upon the Glycocalyx and Endothelial Cells

Bruce D Spiess. J Extra Corpor Technol. 2017 Sep.

Abstract

Unfractionated heparin (UFH) is the most widely used injectable medication in the United States. UFH is a poly-dispersed, relatively impure combination of many polysaccharides known as a glycosaminoglycan. It is used as the primary anticoagulant for heart surgery as well as for active treatment of deep venous thrombosis, vascular thrombosis, stroke, and many other potentially catastrophic clotting syndromes. Many perfusionists and cardiac team members know little of the biology of UFH other than its use for cardiopulmonary bypass. UFH is very similar to heparin sulfate, found on the surface of endothelial cells. Heparan sulfate protects endothelial surfaces from inflammatory attack and serves as a mechano-transducer for vascular shear. UFH and all glycosaminoglycans have far reaching pleotropic actions. This review elaborates on some of fascinating unique biology of these polysaccharides. Perhaps a number of the complex complications attributed to CPB are either caused by, or set up to occur by the complicated biology of UFH?

Keywords: CPB; anticoagulation; ischemia/reperfusion; platelets; thrombosis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Mulloy B, Forster MJ. Conformation and dynamics of heparin and heparan sulfate. Glycobiology. 2000;10:1147–56. - PubMed
    1. Rabenstein DL. Heparin and heparan sulfate: Structure and function. Nat Prod Rep. 2002;19:312–31. - PubMed
    1. Opal SN, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin and heparan sulfate. Crit Care Med. 2002;30:S325–31. - PubMed
    1. Templeton DM. Proteoglycans in cell regulation. Crit Rev Clin Lab Sci. 1992;29:141–84. - PubMed
    1. Fareed J, Hoppenstedt D, Schultz C, et al. . Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Curr Pharm Des. 2004;10:983–99. - PubMed

MeSH terms

LinkOut - more resources